Showing 1291-1300 of 1538 results for "".
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- And the Winner Is...Consumer Reports Releases Annual Sunscreen Ratingshttps://practicaldermatology.com/news/consumer-reports-releases-annual-sunscreen-ratings/2457769/Drumroll please… The annual Consumer Reports sunscreen ratings are in. Just one product, La Roche-Posay Anthelios 60 Melt-In Sunscreen Milk, came
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- DefenAge® Skincare Trio Performs Well in New Studyhttps://practicaldermatology.com/news/defenage-skincare-trio-performs-well-in-new-study/2457818/Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the
- Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Boardhttps://practicaldermatology.com/news/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board/2457834/Israeli-based Kamedis announced the formation of a U.S. medical advisory board. The members include: Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professo
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Episciences Launches New Eczema Creamhttps://practicaldermatology.com/news/episciences-launches-new-eczema-cream/2457851/Episciences, Inc. introduced a new Epionce Renewal Calming Cream, a formula that helps soothe as it replenishes moisture in the skin barrier. Renewal Calming Cream helps relieve the most stubborn symptoms associated with eczema. Ideal for patients with eczema and very dry, sensitive skin, t